A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colo
Fiche publication
Date publication
mai 2013
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent, Pr BOUCHE Olivier
Tous les auteurs :
Köhne CH, Bedenne L, Carrato A, Bouché O, Popov I, Gaspà L, Valladares M, Rougier P, Gog C, Reichardt P, Wils J, Pignatti F, Biertz F
Lien Pubmed
Résumé
To investigate whether infusional high-dose 5-flurouracil (HD-FU) provides a significant improvement in recurrence-free survival (RFS) and overall survival (OS) compared with a standard bolus 5-FU regimen (Mayo Clinic) in patients with curatively resectable stage III colon cancer.
Mots clés
Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Chemotherapy, Adjuvant, Colonic Neoplasms, drug therapy, Diarrhea, chemically induced, Dose-Response Relationship, Drug, Drug Administration Schedule, Europe, Female, Fluorouracil, administration & dosage, Humans, Infusions, Intravenous, Kaplan-Meier Estimate, Leucovorin, administration & dosage, Leukopenia, chemically induced, Male, Middle Aged, Neoplasm Staging, Treatment Outcome, Young Adult
Référence
Eur. J. Cancer. 2013 May;49(8):1868-75